{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:48Z","timestamp":1784347428055,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["23\/659\/A"],"award-info":[{"award-number":["23\/659\/A"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106760","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T07:01:48Z","timestamp":1758178908000},"page":"106760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ethnic and socioeconomic dispensing patterns of disease-modifying therapies for multiple sclerosis in Aotearoa New Zealand"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9911-2082","authenticated-orcid":false,"given":"Natalia","family":"Boven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah F","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarei","family":"Ranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Sporle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Selak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106760_bib0001","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jocn.2015.09.020","article-title":"Disability profile of multiple sclerosis in New Zealand","volume":"28","author":"Alla","year":"2016","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2025.106760_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103012","article-title":"The effectiveness of natalizumab vs fingolimod\u2013a comparison of international registry studies","volume":"53","author":"Andersen","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106760_bib0003","series-title":"NZDep2013 Index of Deprivation","first-page":"1","author":"Atkinson","year":"2014"},{"issue":"3","key":"10.1016\/j.msard.2025.106760_bib0004","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3988\/jcn.2022.0208","article-title":"Current Updates on the Diagnosis and Management of Multiple Sclerosis for the General Neurologist","volume":"19","author":"Baskaran","year":"2023","journal-title":"J. Clin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106760_bib0005","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12913-023-09124-0","article-title":"Disrupted mana and systemic abdication: M\u0101ori qualitative experiences accessing healthcare in the 12\u2009years post-injury","volume":"23","author":"Bourke","year":"2023","journal-title":"BMC Health Serv. Res."},{"issue":"1612","key":"10.1016\/j.msard.2025.106760_bib0006","first-page":"71","article-title":"Identifying multiple sclerosis in linked administrative health data in Aotearoa New Zealand","volume":"138","author":"Boven","year":"2025","journal-title":"N. Z. Med. J."},{"issue":"6","key":"10.1016\/j.msard.2025.106760_bib0007","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s10072-023-06608-z","article-title":"The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis","volume":"44","author":"Boz","year":"2023","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2025.106760_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.anzjph.2024.100149","article-title":"M\u0101ori and Pacific families\u2019 experiences and perspectives of cardiovascular care; a qualitative study","volume":"48","author":"Brewer","year":"2024","journal-title":"Aust. N. Z. J. Public Health"},{"key":"10.1016\/j.msard.2025.106760_bib0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12939-025-02436-z","article-title":"Addressing health equity during design and implementation of health system reform initiatives: a scoping review and framework","volume":"24","author":"Bouckley","year":"2025","journal-title":"Int. J. Equity Health"},{"key":"10.1016\/j.msard.2025.106760_bib0010","series-title":"Brain Health\u2014Time Matters","author":"Butzkueven","year":"2024"},{"issue":"10","key":"10.1016\/j.msard.2025.106760_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038861","article-title":"Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study","volume":"10","author":"Butzkueven","year":"2020","journal-title":"BMJ Open."},{"issue":"2","key":"10.1016\/j.msard.2025.106760_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191646","article-title":"Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients","volume":"13","author":"Calocer","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.msard.2025.106760_bib0013","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/13524585211035948","article-title":"The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis","volume":"28","author":"Claflin","year":"2022","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2025.106760_bib0014","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/jnnp-2024-333338","article-title":"Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre study","volume":"95","author":"Das","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106760_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103474","article-title":"The association between deprivation and the access to disease modifying therapies for multiple sclerosis: an England wide community-based study in the UK MS Register","volume":"57","author":"Das","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1546","key":"10.1016\/j.msard.2025.106760_bib0016","first-page":"47","article-title":"Barriers and facilitators for M\u0101ori in accessing hospital services in Aotearoa New Zealand","volume":"134","author":"Espiner","year":"2021","journal-title":"N. Z. Med. J."},{"key":"10.1016\/j.msard.2025.106760_bib0017","series-title":"New Zealand Socio-Economic Index 2013","author":"Fahy","year":"2017"},{"key":"10.1016\/j.msard.2025.106760_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103052","article-title":"Maternal education has significant influence on progression in multiple sclerosis","volume":"53","author":"Flemmen","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106760_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103759","article-title":"The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort","volume":"61","author":"Flemmen","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106760_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102967","article-title":"Socioeconomic status and access to multiple sclerosis treatment in Mexico","volume":"52","author":"G\u00f3mez-Figueroa","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106760_bib0021","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/1753-6405.12971","article-title":"Experiences of M\u0101ori of Aotearoa New Zealand\u2019s public health system: a systematic review of two decades of published qualitative research","volume":"44","author":"Graham","year":"2020","journal-title":"Aust. N. Z. J. Public Health"},{"key":"10.1016\/j.msard.2025.106760_bib0022","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12939-023-02087-y","article-title":"Adapting an equity-focused implementation process framework with a focus on ethnic health inequities in the Aotearoa New Zealand context","volume":"23","author":"Gustafson","year":"2024","journal-title":"Int. J. Equity Health"},{"issue":"1","key":"10.1016\/j.msard.2025.106760_bib0023","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12889-023-17603-6","article-title":"The impact of racism on subsequent healthcare use and experiences for adult New Zealanders: a prospective cohort study","volume":"24","author":"Harris","year":"2024","journal-title":"BMC Public Health"},{"issue":"1567","key":"10.1016\/j.msard.2025.106760_bib0024","first-page":"54","article-title":"We still don\u2019t count: the under-counting and under-representation of M\u0101ori in health and disability sector data","volume":"135","author":"Harris","year":"2022","journal-title":"N. Z. Med. J."},{"issue":"6","key":"10.1016\/j.msard.2025.106760_bib0025","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/fampra\/cmad096","article-title":"Financial barriers to primary health care in Aotearoa New Zealand","volume":"41","author":"Jeffreys","year":"2024","journal-title":"Fam. Pract."},{"issue":"7","key":"10.1016\/j.msard.2025.106760_bib0026","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp-2022-330582","article-title":"Multiple sclerosis mortality in New Zealand: a nationwide prospective study","volume":"94","author":"Leadbetter","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106760_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1197212","article-title":"Impact of aging on treatment considerations for multiple sclerosis patients","volume":"14","author":"Macaron","year":"2023","journal-title":"Front. Neurol."},{"issue":"1393","key":"10.1016\/j.msard.2025.106760_bib0028","first-page":"52","article-title":"Initiation of maternity care for young M\u0101ori women under 20 years of age","volume":"127","author":"Makowharemahihi","year":"2014","journal-title":"N. Z. Med. J."},{"issue":"8","key":"10.1016\/j.msard.2025.106760_bib0029","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2025.106760_bib0030","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.3389\/fimmu.2019.02954","article-title":"Multiple sclerosis and cancer: the Ying-Yang effect of disease modifying therapies","volume":"10","author":"Melamed","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2025.106760_bib0031","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/ije\/dyz014","article-title":"Data resource profile: the New Zealand Integrated Data Infrastructure (IDI)","volume":"48","author":"Milne","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.msard.2025.106760_bib0032","series-title":"Ocrelizumab Subcut Receives Medsafe Registration as Pressure Mounts to Fund Wider Range of MS Treatment Options","year":"2025"},{"issue":"2","key":"10.1016\/j.msard.2025.106760_bib0033","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10198-012-0378-7","article-title":"Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom","volume":"14","author":"Owens","year":"2013","journal-title":"Eur. J. Health Econ."},{"issue":"14","key":"10.1016\/j.msard.2025.106760_bib0034","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1177\/1352458514535130","article-title":"Multiple sclerosis in New Zealand M\u0101ori","volume":"20","author":"Pearson","year":"2014","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106760_bib0035","first-page":"205","article-title":"Partial proportional odds models for ordinal response variables","volume":"39","author":"Peterson","year":"1990","journal-title":"J. R. Stat. Soc., C: Appl. Stat."},{"key":"10.1016\/j.msard.2025.106760_bib0036","series-title":"Multiple Sclerosis Treatments Funding Proposal","year":"2014"},{"key":"10.1016\/j.msard.2025.106760_bib0037","series-title":"Decisions Relating to Multiple Sclerosis Treatments","year":"2014"},{"key":"10.1016\/j.msard.2025.106760_bib0038","series-title":"New Treatment Options for Patients with Multiple Sclerosis","year":"2015"},{"key":"10.1016\/j.msard.2025.106760_bib0039","series-title":"Decision to Fund Oncology, Multiple Sclerosis and Respiratory Treatments","year":"2019"},{"key":"10.1016\/j.msard.2025.106760_bib0040","series-title":"Decision for Funded Multiple Sclerosis Treatments","year":"2021"},{"key":"10.1016\/j.msard.2025.106760_bib0041","series-title":"Decision to Fund Treatment Earlier for Relapsing Remitting Multiple Sclerosis","year":"2022"},{"key":"10.1016\/j.msard.2025.106760_bib0042","series-title":"Pharmac Funds First Treatment for Primary Progressive Multiple Sclerosis","year":"2023"},{"key":"10.1016\/j.msard.2025.106760_bib0043","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.msard.2019.01.037","article-title":"Differential multiple sclerosis treatment allocation between Australia and New Zealand associated with clinical outcomes but not mood or quality of life","volume":"30","author":"Phyo","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1393","key":"10.1016\/j.msard.2025.106760_bib0044","first-page":"107","article-title":"Improving M\u0101ori health through clinical assessment: Waikare o te Waka o Meihana","volume":"127","author":"Pitama","year":"2014","journal-title":"N. Z. Med. J."},{"key":"10.1016\/j.msard.2025.106760_bib0045","series-title":"R: A language and Environment for Statistical Computing [Computer Software]","year":"2022"},{"key":"10.1016\/j.msard.2025.106760_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fstro.2023.1248351","article-title":"Stroke among M\u0101ori in Aotearoa New Zealand and solutions to address persistent inequities","volume":"2","author":"Ranta","year":"2023","journal-title":"Front. Stroke"},{"issue":"1419","key":"10.1016\/j.msard.2025.106760_bib0047","first-page":"35","article-title":"New Zealand\u2019s neurologist workforce: a pragmatic analysis of demand, supply and future projections","volume":"128","author":"Ranta","year":"2015","journal-title":"N. Z. Med. J."},{"key":"10.1016\/j.msard.2025.106760_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102024","article-title":"Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis","volume":"41","author":"Reyes","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106760_bib0049","series-title":"SAS Enterprise Guide 8.3 [Computer Software]","year":"2020"},{"key":"10.1016\/j.msard.2025.106760_bib0050","article-title":"Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1","author":"Shipley","year":"2025","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.msard.2025.106760_bib0051","series-title":"Microdata Output Guide: Fifth Edition","year":"2020"},{"key":"10.1016\/j.msard.2025.106760_bib0052","series-title":"Experimental Administrative Population Census: Data Sources, Methods, and Quality (Second Iteration)","year":"2022"},{"issue":"12","key":"10.1016\/j.msard.2025.106760_bib0053","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1177\/1352458510379614","article-title":"MS prevalence in New Zealand, an ethnically and latitudinally diverse country","volume":"16","author":"Taylor","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106760_bib0054","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211028007","article-title":"Inequities in people with gout: a focus on M\u0101ori (Indigenous People) of Aotearoa New Zealand","volume":"13","author":"Te Karu","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"1607","key":"10.1016\/j.msard.2025.106760_bib0055","first-page":"87","article-title":"Cultural safety and the medical profession in Aotearoa New Zealand: a training framework and the pursuit of M\u0101ori health equity","volume":"137","author":"Tipene-Leach","year":"2024","journal-title":"N. Z. Med. J."},{"key":"10.1016\/j.msard.2025.106760_bib0056","series-title":"WG Short Set on Functioning (WG-SS)","year":"2022"},{"key":"10.1016\/j.msard.2025.106760_bib0057","first-page":"27","article-title":"Comparison of the sociodemographic composition of rural and urban Aotearoa New Zealand: insights from applying the geographic classification for health to the 2018 census","volume":"49","author":"Whitehead","year":"2023","journal-title":"N. Z. Popul. Rev."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:36:21Z","timestamp":1784345781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":57,"alternative-id":["S2211034825005024"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106760","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ethnic and socioeconomic dispensing patterns of disease-modifying therapies for multiple sclerosis in Aotearoa New Zealand","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106760"}}